Skip to content

Study · In vitro (cells) · pseudomonas aeruginosa · 2021

5 results

Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates.

Díez-Aguilar M, Ekkelenkamp M, Morosini MI, Huertas N, Del Campo R, Zamora J, Fluit AC, Tunney MM, Obrecht D, Bernardini F, Cantón R

The Journal of antimicrobial chemotherapy1 Sept 2021Cited by 20 (Europe PMC)

PMID34283223 (opens in a new tab)DOI10.1093/jac/dkab222 (opens in a new tab)PepBankPUB-34283223
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cystic fibrosis isolates, murepavadin had MBIC50/MBIC90 values of 2/32, similar to colistin and tobramycin.

    In plain wordsIn lab tests, murepavadin had biofilm inhibitory concentrations similar to colistin and tobramycin.

    Peptide
    Murepavadin
    Outcome
    Not applicableMBIC50 and MBIC90
    Study

    Pseudomonas aeruginosan = 53

    Cystic fibrosis isolates in biofilms
    Comparator
    Colistin and tobramycin
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Colistin, tobramycin and murepavadin presented similar MBIC50/MBIC90 values (4/32, 8/64 and 2/32, respectively).
    1 context sentence
    Summary · context
    The minimal biofilm inhibitory concentration (MBIC) and the minimal biofilm eradication concentration (MBEC) were determined.
  2. 02LabIn vitro (cells)Activity measurement

    In cystic fibrosis isolates, murepavadin had the lowest MBEC90, at 64 mg/L.

    In plain wordsIn lab tests, murepavadin had the lowest concentration needed to eradicate most biofilms among the tested antibiotics.

    Peptide
    Murepavadin
    Outcome
    DecreaseMBEC90
    Study

    Pseudomonas aeruginosan = 53

    Cystic fibrosis isolates in biofilms
    Comparator
    Other tested antibiotics
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    MBEC90
    64 mg/L
    Not specified

    Source sentences

    Summary
    Murepavadin exhibited the lowest MBEC90 (64 mg/L).
    1 context sentence
    Summary · context
    The minimal biofilm inhibitory concentration (MBIC) and the minimal biofilm eradication concentration (MBEC) were determined.
  3. 03LabIn vitro (cells)Activity measurement

    In cystic fibrosis isolates, murepavadin MBEC-ECOFF was 128 mg/L, versus 64 mg/L for tobramycin and above 512 mg/L for aztreonam and colistin.

    In plain wordsIn lab tests, murepavadin's biofilm eradication cutoff was higher than tobramycin's and lower than those of aztreonam and colistin.

    Peptide
    Murepavadin
    Outcome
    Not applicableMBEC-ECOFF
    Study

    Pseudomonas aeruginosan = 53

    Cystic fibrosis isolates in biofilms
    Comparator
    Tobramycin, aztreonam and colistin
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    MBEC-ECOFF
    128 mg/L
    Not specified

    Source sentences

    Summary
    Tobramycin and murepavadin had the lowest MBEC-ECOFF (64 and 128 mg/L, respectively), while those of aztreonam and colistin exceeded 512 mg/L.
    1 context sentence
    Summary · context
    The minimal biofilm inhibitory concentration (MBIC) and the minimal biofilm eradication concentration (MBEC) were determined.
  4. 04LabIn vitro (cells)Activity measurement

    In BioFlux experiments, murepavadin-treated PAO1, PAO mutS and smooth clinical biofilms differed significantly in fluorescence from untreated biofilms.

    In plain wordsIn lab tests, treated biofilms differed in fluorescence from untreated biofilms for three strains.

    Peptide
    Murepavadin
    Outcome
    Direction not reportedBiofilm fluorescence
    Study

    Pseudomonas aeruginosan: not reported in source

    BioFlux PAO1, PAO mutS and smooth clinical strain biofilms
    Comparator
    Untreated biofilms
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Using the BioFlux, for the PAO1, PAO mutS and the smooth clinical strain, a significant difference (P < 0.0125) was observed when comparing the fluorescence of treated and untreated biofilms.
    1 context sentence
    Summary · context
    The minimal biofilm inhibitory concentration (MBIC) and the minimal biofilm eradication concentration (MBEC) were determined.
  5. 05LabIn vitro (cells)Activity measurement

    In the mucoid strain, murepavadin-treated biofilms did not show fluorescence differences from untreated biofilm.

    In plain wordsIn lab tests, murepavadin-treated mucoid biofilms did not differ in fluorescence from untreated biofilms.

    Peptide
    Murepavadin
    Outcome
    No significant changeMucoid biofilm fluorescence
    Study

    Pseudomonas aeruginosan: not reported in source

    BioFlux mucoid strain biofilm
    Comparator
    Untreated biofilm
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    For the mucoid strain, only the biofilm treated with aztreonam (MBIC and MBEC) and tobramycin (MBEC) showed differences with respect to the untreated biofilm.
    2 context sentences
    Summary · context
    To determine the activity of murepavadin in comparison with tobramycin, colistin and aztreonam, against cystic fibrosis (CF) Pseudomonas aeruginosa isolates growing in biofilms.
    Summary · context
    The minimal biofilm inhibitory concentration (MBIC) and the minimal biofilm eradication concentration (MBEC) were determined.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.